Role of BRAF in Hepatocellular Carcinoma: A Rationale for Future Targeted Cancer Therapies

The few therapeutic strategies for advance hepatocellular carcinoma (HCC) on poor knowledge of its biology. For several years, sorafenib, a tyrosine kinase inhibitors (TKI) inhibitor, has been the approved treatment option, to date, for advanced HCC patients. Its activity is the inhibition of the re...

Descripción completa

Detalles Bibliográficos
Autores principales: Gnoni, Antonio, Licchetta, Antonella, Memeo, Riccardo, Argentiero, Antonella, Solimando, Antonio G., Longo, Vito, Delcuratolo, Sabina, Brunetti, Oronzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6956203/
https://www.ncbi.nlm.nih.gov/pubmed/31766556
http://dx.doi.org/10.3390/medicina55120754

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6956203/
https://www.ncbi.nlm.nih.gov/pubmed/31766556
http://dx.doi.org/10.3390/medicina55120754

Ejemplares similares